Pathogenicity, Antibiotic Resistance, and Metabolites in Enterococci
Article Sidebar
-
Enterococci, Antibiotic Resistance, Metabolites, Pathogenicity
Abstract
Enterococci have been connected to major infections, decreased output in the grow-out ponds and hatchery, and lowered growth rates and feed conversion in individuals that have survived the outbreak. All of these factors have had a negative impact on the overall financial productivity of the organization. The most typical steps in the pathogenesis of infectious enterococci are establishment, adhering to the cell structure of the host, tissue invasion, and an unspecific resistance defensive mechanism. Infections brought on by enterococci that displayed virulence phenotypically were shown to be more severe than those brought on by enterococci that did not express virulence in any way, according to the research that was written up and published. Because of the elevated mechanism of enterococci as causative agents that cause infections in patients whose immunity is compromised, additional research has been energized to characterize the elements and/or factors that allow bacteria to inhabit the host effectively through the barriers of the immune system, causing pathological alterations. This is being done because of the elevated mechanism of enterococci as causative agents that cause infections in patients with a compromised immune system. This is as a result of the enhanced mechanism of enterococci as a causal agent that causes infections in people whose immune systems have been impaired.
Full text article
References
MacCallum WG and Hastings TW. 1899 A Case of Acute Endocarditis Caused by Micrococcus Zymogenes (Nov. Spec.), Together with a Description of the Microorganism. Journal of Experimental Medicine 4:521–534.
Yehia N, Aly A, Al-Mousa HH, Sayed E, and Al Asar M. Infections acquired at a medical-surgical intensive care unit in 2008 due to a nosocomial source. Med Principles and Practice 17:373–377.
C.J. Kristich, L.B. Rice, and C.A. Arias. 2014 Enterococcal Infection: Treatment Options and the Development of Antibiotic Resistance. Drug-Resistant Infections Can Be Caused by Enterococci Ranging from Commensals to Lead.
Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, and Fridkin SK were the researchers who contributed to this study. Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 for the National Healthcare Safety N. Source Infect Control Hosp Epidemiol Infect Control Hosp Epidemiol 29. 2008
Y. Ike, M. S. Gilmore, D. B. Clewell, and N. Shankar. 2014 Enterococci Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. 2014 Enterococci Enterococci.
EGGESB M, MOEN B, PEDDADA S, BAIRD D, RUGTVEIT J, MIDTVEDT T, BUSHEL PR, SEKELJA M, RUDI K. EGGESB M, MOEN B, PEDDADA S, BAIRD D. 2011 Research on the development of the microbiota in the guts of infants who were not subjected to any medical procedures. APMIS 119, verses 17 to 35.
Both Lawley and Walker were TD. 2013 Resistance to intestinal colonization in 2013. 138:1–11 of the journal Immunology.
Both A. Jung and S. Rautenschlein. 2014 Detailed report of an infection caused by Enterococcus cecorum in a broiler flock in Northern Germany. BMC Veterinary Research 2010:311.
Martin J.D. and John O. Mundt. 1972 The First Report of Enterococci in Insects. Applied and Environmental Microbiology 24:575–580.
Mundt, Joseph O. 1963 The discovery of enterococci living on plants in their natural environment. 11:141–4 of the journal Appl. Microbiol.
Schleifer K.H. and R. Kilpper-Balz. The bacteria Streptococcus faecalis and Streptococcus faecium were moved into the genus Enterococcus norn in the year 1984. once known as comb. Enterococcus faecalis. in addition to Enterococcus faecium comb. nov. nov. Int. J. Syst. Bacteriol., International Union of Microbiological Societies, 34:31–34.
2017 Tracing the Enterococci from Paleozoic Origins to the Hospital by Lebreton F, Manson AL, Saavedra JT, Straub TJ, Earl AM, and Gilmore MS. 849–861.e13 on cell number 169.
Xavier JB, Lipuma L, Ubeda C, Goldberg J. 2012 Intestinal dominance and the risk of bacteremia in patients who were receiving allogeneic hematopoietic stem cell transplantation. The Clinical Infectious Diseases 55:905–914.
The authors' names are Moellering RC, Wennersten C, and Weinberg AN. Penicillin and gentamicin worked together more effectively against enterococci in 1971. Reference: Journal of Infectious Diseases 124:207–209.
JJ, Gilmore KS, Courvalin P. 167:631-638 in Journal of Bacteriology. [Publication Number: 3015884]
Murray BE. Enterococci producing beta-lactamase in the year 1992. Antibacterial and Chemotherapeutic Agents and Chemotherapy 36:2355–2359. [Publication Number: 1489177]
JE Geraci, FR Heilman, DR Nichols, GT Ross, and WE Wellman are the authors of this study. Some laboratory and clinical experiences with the newly discovered antibiotic vancomycin in 1956. Mayo Clinic Proceedings, Volume 31: page 564 to page 582.
Kaye D., Rahimtoola SH, Bisno AL, Dismukes WE, Durack DT, Kaplan EL, Karchmer AW, Sande MA, Sanford JP, Watanakunakorn C, and Wilson WR. Antimicrobial Treatment of Infectious Endocarditis Caused by Viridans Streptococci, Enterococci, and Staphylococci (published in 1989). JAMA (Journal of the American Medical Association) 261, page 1471.
HA Kirst, DG Thompson, and TI Nicas. 1998 was the historical year in which vancomycin was used [1]. Chemotherapy using Antimicrobial Agents.
Uttley AH, Collins CH, Naidoo J, and George RC. 1988 Enterococci resistant to the antibiotic vancomycin. 1:57–58 of the Lancet.
Kissinger J., Sahm DF, Gilmore MS, Murray PR, Mulder R., Solliday J., and Clarke B. Vancomycin-resistant Enterococcus faecalis was subjected to in vitro susceptibility tests in the year 1989. Chemotherapy and Antimicrobial Agents 33:1588–1591.
CA Arias and BE Murray were cited. 2008 A review of the emergence of drug-resistant enterococcal infections and their management was published in the Expert Review of Anti-Infective Therapy. Taylor & Francis, if you will.#
Lesho E, Wortmann GW, Craft D, and Moran KA. 2006 Letters to the Editor De Novo Daptomycin Nonsusceptibility in a Clinical Isolate. J Clin Microbiol 44.
Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. 2005 DAPTOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid Leukemia CASE REPORT. Mayo Clin Proc 80:1215–1216.
Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. 2011 Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 55:3345–3356. [PubMed: 21502617]
Saito HE, Harp JR, Fozo EM. 2014 Incorporation of exogenous fatty acids protects Enterococcus faecalis from membrane-damaging agents. Appl Environ Microbiol 80:6527–6538. [PubMed: 25128342]
Hines KM, Waalkes A, Penewit K, Holmes EA, Salipante SJ, Werth BJ, Xu L. Characterization of the Mechanisms of Daptomycin Resistance among Gram- Positive Bacterial Pathogens by Multidimensional Lipidomics.
Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP. 2002 Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50:743–6. [PubMed: 12407134]
Bourgeois‐Nicolaos N, Massias L, Couson B, Butel M, Andremont A, Doucet-Populaire F. 2007 Dose Dependence of Emergence of Resistance to Linezolid in Enterococcus faecalis In Vivo. J Infect Dis 195:1480–1488. [PubMed: 17436228]
Cattoir V, Isnard C, Cosquer T, Odhiambo A, Bucquet F, Guérin F, Giard J-C. 2015 Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium. Antimicrob Agents Chemother 59:239–44. [PubMed: 25348531]
Figdor D, Davies JK, Sundqvist G. 2003 Starvation survival, growth and recovery of Enterococcus faecalis in human serum. Oral Microbiol Immunol 18:234–239. [PubMed: 12823799]
Heim S, Del Mar Lleo M, Bonato B, Guzman CA, Canepari P. 2002 The Viable but Nonculturable State and Starvation Are Different Stress Responses of Enterococcus faecalis, as Determined by Proteome Analysis. J Bacteriol 184:6739–6745. [PubMed: 12426365]
Flahaut S, Frere J, Boutibonnes P, Auffray Y. 1996 Comparison of the bile salts and sodium dodecyl sulfate stress responses in Enterococcus faecalis. Appl Environ Microbiol 62:2416–2420. [PubMed: 8779581]
Flahaut S, Hartke A, Giard JC, Auffray Y. 1997 Alkaline stress response in Enterococcus faecalis: adaptation, cross-protection, and changes in protein synthesis. Appl Environ Microbiol 63:812–4. [PubMed: 9023964]
Giard JC, Hartke A, Flahaut S, Boutibonnes P, Auffray Y. 1997 Glucose starvation response in Enterococcus faecalis JH2–2: Survival and protein analysis. Res Microbiol 148:27–35.
Laplace JM, Thuault M, Hartke A, Boutibonnes P, Auffray Y. 1997 Sodium hypochlorite stress in Enterococcus faecalis: Influence of antecedent growth conditions and induced proteins. Curr Microbiol 34:284–289. [PubMed: 9099628]
Le Breton Y, Boël G, Benachour A, Prévost H, Auffray Y, Rincé A. 2003 Molecular characterization of Enterococcus faecalis two-component signal transduction pathways related to environmental stresses. Environ Microbiol 5:329–337. [PubMed: 12713459]
Garsin DA, Frank KL, Silanpää J, Ausubel FM, Hartke A, Shankar N, Murray BE. 2014 Pathogenesis and Models of Enterococcal InfectionEnterococci: From Commensals to Leading Causes of Drug Resistant Infection. Massachusetts Eye and Ear Infirmary.
Johnson A 1994 The pathogenicity of enterococci. FEMS Microbiol Rev 33:1083–1089.
Noble CJ. 1978 Carriage of group D streptococci in the human bowel. J Clin Pathol 31:1182–1186. [PubMed: 107199]
Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, eds. (2000). Gram-Positive Pathogens. ASM Press.
Fisher K, Phillips C (June 2009). "The ecology, epidemiology and virulence of Enterococcus". Microbiology. 155 (Pt 6): 1749–57.
Schleifer KH, Kilpper-Balz R (1984). "Transfer of Streptococcus faecalis and Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov". Int. J. Syst. Bacteriol. 34: 31–34.
Lebreton F, Manson AL, Saavedra JT, Straub TJ, Earl AM, Gilmore MS (2017) Tracing the Enterococci from Paleozoic origins to the hospital. Cell 169(5):849-861.e13. doi: 10.1016/j.cell.2017.04.02
Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 294–5. ISBN 0-8385-8529-9.
Fiore, Marco; Maraolo, Alberto Enrico; Gentile, I. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis". World Journal of Hepatology. 2017; 9 (30): 1166–1175.
Pelletier LL Jr. (1996). "Microbiology of the Circulatory System". In Baron S; et al. (eds.). Baron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1.
Zhanel GG, Hoban DJ, Karlowsky JA (January 2001). "Nitrofurantoin is active against vancomycin-resistant enterococci". Antimicrobial Agents and Chemotherapy. 45 (1): 324–6.
Guardado R, Asensi V, Torres JM, Pérez F, Blanco A, Maradona JA, Cartón JA (2006). "Post-surgical enterococcal meningitis: clinical and epidemiological study of 20 cases". Scandinavian Journal of Infectious Diseases. 38 (8): 584–8.
Kurup A, Chlebicki MP, Ling ML, Koh TH, Tan KY, Lee LC, Howe KB (April 2008). "Control of a hospital-wide vancomycin-resistant Enterococci outbreak". American Journal of Infection Control. 36 (3): 206–11.
Batts, D. H.; Lavin, B. S.; Eliopoulos, G. M. (2001). "Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report". Current Clinical Topics in Infectious Diseases. 21: 227–251. ISSN 0195-3842. PMID 11572153
Collins, L A; Malanoski, G J; Eliopoulos, G M; Wennersten, C B; Ferraro, M J; Moellering, R C (March 1993). "In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms". Antimicrobial Agents and Chemotherapy. 37 (3): 598–601. doi:10.1128/aac.37.3.598. ISSN 0066-4804. PMC 187713. PMID 8460927.
Singh, Kavindra V.; Weinstock, George M.; Murray, Barbara E. (June 2002). "An Enterococcus faecalis ABC Homologue (Lsa) Is Required for the Resistance of This Species to Clindamycin and Quinupristin-Dalfopristin". Antimicrobial Agents and Chemotherapy. 46 (6): 1845–1850.
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.